AI vision for pharmaceutical manufacturing: tablet and capsule inspection
AI vision for pharmaceutical manufacturing: tablet and capsule inspection
Pharmaceutical manufacturers in Singapore and Malaysia face a simple choice: inspect every tablet that leaves your line, or inspect a sample and hope the rest is fine.
Manual AQL sampling means you are statistically confident. It does not mean you are certain. With 100% inline AI vision inspection, certainty is the baseline, not the goal.
What pharmaceutical manufacturers are actually trying to solve
Visual defects in solid dose manufacturing fall into a few clear categories. Tablets chip at the press. Coated tablets develop discoloration from moisture exposure or pan temperature variation. Print defects on film-coated tablets, logos, score lines, and embossed text go out of register or smear entirely.
Capsules present a different set of problems. Fill weight is controlled by the filling machine, but visual fill-level inspection catches jams, partially filled bodies, and cap misalignment before packing. Blister pack seal integrity is a separate inspection point entirely, where a weak seal or unsealed pocket creates a compliance and shelf-life problem.
Each of these defect types has a different visual signature. A rule-based vision system requires engineers to pre-program every signature. A trained AI model learns them from examples.
Why manual AQL sampling is not enough for modern GMP requirements
The HSA GMP guidelines and FDA 21 CFR Part 211 both require documented visual inspection with demonstrated capability to detect defects at defined acceptance quality levels. Manual AQL sampling satisfies this requirement statistically. It inspects a defined subset and draws conclusions about the batch.
The gap is what happens between samples.
A chipping event at tablet press station 6 produces defective units for however long it runs undetected. A discoloration streak on coated tablets may affect 3,000 units before an AQL sample catches it at end-of-batch review. By then, the batch is complete, and the investigation cost exceeds the product value.
100% inline inspection changes the economics. Every unit passes through the inspection station. Defective units are rejected in real time. The production line keeps running and the defect data is timestamped and logged automatically against the batch record.
This is the documentation trail that regulators want to see.
How HyperQ AI Vision handles pharmaceutical inspection
HyperQ AI Vision is built on a model base trained across 8,000+ manufacturing deployments. For pharmaceutical lines, the inspection workflow covers:
- Tablet visual defects: chipping, capping, edge chips, surface discoloration, coating defects, print registration errors, embossing defects
- Capsule inspection: fill-level verification, cap-body alignment, surface contamination
- Blister pack integrity: seal completeness, pocket fill confirmation, foil deformation detection
Detection performance reaches 99% accuracy on trained defect classes. The training baseline requires approximately 1,000 images per defect type, which is achievable during a standard validation run on a production line.
The system logs every inspection decision with image capture, timestamp, and defect classification. This output feeds directly into batch records and is formatted for GMP audit review.
What this means for regulatory compliance documentation
GMP visual inspection documentation has two components: the inspection itself, and proof that the inspection system was validated and capable.
With manual inspection, capability is demonstrated through operator qualification records and periodic AQL audits. With AI vision, capability is demonstrated through model validation reports, detection rate benchmarks against known defect sets, and the continuous inspection log from production.
For HSA audits in Singapore and Malaysian Ministry of Health GMP reviews, this log is more complete than anything a manual process can provide. Every unit is accounted for. Every defect is traceable. The data exists because the system captures it automatically.
Comparing the approaches
| Manual AQL sampling | HyperQ AI Vision | |
|---|---|---|
| Coverage | Statistical sample | 100% of units |
| Detection latency | End of batch or mid-batch spot check | Real time, per unit |
| Documentation | Operator records, AQL worksheets | Automated batch log with image archive |
| Defect traceability | Batch level | Unit level, timestamped |
| Validation for GMP | Operator qualification | Model validation report + continuous performance data |
Getting started on a pharmaceutical line
For most pharmaceutical manufacturers, the first question is whether the existing line can accommodate an inline inspection station without disrupting throughput.
HyperQ AI Vision deploys on existing conveyors and packaging lines. Camera placement, lighting, and model training are configured to your specific product forms and defect specifications. There is no requirement to replace hardware-bundled vision system providers already on your line for other functions.
If you are running tablet press, coating pan, encapsulation, and blister packaging as separate operations, each can be inspected independently with its own trained model.
The practical starting point for most Singapore and Malaysia pharmaceutical manufacturers is a pilot on one product form, one production line, with a defined defect set. This generates the validation data you need for GMP documentation and gives your quality team real performance numbers before full deployment.
Want to see how AI vision would fit your specific tablet or capsule line? Send your line details and defect list through to our team and we will put together a practical assessment: https://apac.hypernology.net/contact
For more context on how defect detection works in manufacturing generally, read our complete guide to defect detection in manufacturing. To see the full range of HyperQ applications, visit our solutions page.